PDCD1 and neoplasm: Studies have shown that CTLA-4 or PD-1 inhibitors can reduce tumor vascular density, improve vascular perfusion, relieve hypoxia of tumor tissue, normalize blood vessels, and reduce the immunosuppressive effect of Treg, TAMS, and MDSCs (44–46).